|
1
|
International Agency for Research on
Cancer, World Health Organization, . GLOBOCAN 2012: Estimated
cancer incidence, mortality and prevalence worldwide in 2012.
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspxAccessed
July 31, 2015.
|
|
2
|
Devesa SS, Bray F, Vizcaino AP and Parkin
DM: International lung cancer trends by histologic type: Male:
Female differences diminishing and adenocarcinoma rates rising. Int
J Cancer. 117:294–299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: Recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Forde PM and Ettinger DS: Targeted therapy
for non-small-cell lung cancer: Past, present and future. Expert
Rev Anticancer Ther. 13:745–758. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gridelli C, Peters S, Sgambato A, Casaluce
F, Adjei AA and Ciardiello F: ALK inhibitors in the treatment of
advanced NSCLC. Cancer Treat Rev. 40:300–306. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamada A, Sasada T, Noguchi M and Itoh K:
Next-generation peptide vaccines for advanced cancer. Cancer Sci.
104:15–21. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sasada T, Yamada A, Noguchi M and Itoh K:
Personalized peptide vaccine for treatment of advanced cancer. Curr
Med Chem. 21:2332–2345. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Terazaki Y, Yoshiyama K, Matsueda S,
Watanabe N, Kawahara A, Naito Y, Suekane S, Komatsu N, Ioji T,
Yamada A, et al: Immunological evaluation of personalized peptide
vaccination in refractory small cell lung cancer. Cancer Sci.
103:638–644. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoshiyama K, Terazaki Y, Matsueda S,
Shichijo S, Noguchi M, Yamada A, Mine T, Ioji T, Itoh K, Shirouzu
K, et al: Personalized peptide vaccination in patients with
refractory non-small cell lung cancer. Int J Oncol. 40:1492–1500.
2012.PubMed/NCBI
|
|
10
|
Waki K, Yamada T, Yoshiyama K, Terazaki Y,
Sakamoto S, Matsueda S, Komatsu N, Sugawara S, Takamori S, Itoh K
and Yamada A: PD-1 expression on peripheral blood T-cell subsets
correlates with prognosis in non-small cell lung cancer. Cancer
Sci. 105:1229–1235. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gutteridge JM: The antioxidant activity of
haptoglobin towards haemoglobin-stimulated lipid peroxidation.
Biochim Biophys Acta. 917:219–223. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gutteridge JM and Smith A: Antioxidant
protection by haemopexin of haem-stimulated lipid peroxidation.
Biochem J. 256:861–865. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thompson S and Turner GA: Elevated levels
of abnormally-fucosylated haptoglobins in cancer sera. Br J Cancer.
56:605–610. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Okuyama N, Ide Y, Nakano M, Nakagawa T,
Yamanaka K, Moriwaki K, Murata K, Ohigashi H, Yokoyama S, Eguchi H,
et al: Fucosylated haptoglobin is a novel marker for pancreatic
cancer: A detailed analysis of the oligosaccharide structure and a
possible mechanism for fucosylation. Int J Cancer. 118:2803–2808.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fujimura T, Shinohara Y, Tissot B, Pang
PC, Kurogochi M, Saito S, Arai Y, Sadilek M, Murayama K, Dell A, et
al: Glycosylation status of haptoglobin in sera of patients with
prostate cancer vs. Benign prostate disease or normal subjects. Int
J Cancer. 122:39–49. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ahmed N, Barker G, Oliva KT, Hoffmann P,
Riley C, Reeve S, Smith AI, Kemp BE, Quinn MA and Rice GE:
Proteomic-based identification of haptoglobin-1 precursor as a
novel circulating biomarker of ovarian cancer. Br J Cancer.
91:129–140. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao C, Annamalai L, Guo C, Kothandaraman
N, Koh SC, Zhang H, Biswas A and Choolani M: Circulating
haptoglobin is an independent prognostic factor in the sera of
patients with epithelial ovarian cancer. Neoplasia. 9:1–7. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dowling P, Clarke C, Hennessy K,
Torralbo-Lopez B, Ballot J, Crown J, Kiernan I, O'Byrne KJ, Kennedy
MJ, Lynch V and Clynes M: Analysis of acute-phase proteins, AHSG,
C3, CLI, HP and SAA, reveals distinctive expression patterns
associated with breast, colorectal and lung cancer. Int J Cancer.
131:911–923. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hoagland LF IV, Campa MJ, Gottlin EB,
Herndon JE II and Patz EF Jr: Haptoglobin and posttranslational
glycan-modified derivatives as serum biomarkers for the diagnosis
of nonsmall cell lung cancer. Cancer. 110:2260–2268. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hansen JE, Iversen J, Lihme A and
Bøg-Hansen TC: Acute phase reaction, heterogeneity, and
microheterogeneity of serum proteins as nonspecific tumor markers
in lung cancer. Cancer. 60:1630–1635. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Teye K, Soejima M, Quaye IK, Pang H,
Tsuneoka M, Koda Y and Kimura H: Haptoglobin gene promoter
polymorphism and haplotypes are unique in different populations.
Hum Biol. 78:121–126. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Soejima M, Sagata N, Komatsu N, Sasada T,
Kawaguchi A, Itoh K and Koda Y: Genetic factors associated with
serum haptoglobin level in a Japanese population. Clin Chim Acta.
433:54–57. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Noguchi M, Itoh K, Suekane S, Morinaga A,
Sukehiro A, Suetsugu N, Katagiri K, Yamada A and Noda S:
Immunological monitoring during combination of patient-oriented
peptide vaccination and estramustine phosphate in patients with
metastatic hormone refractory prostate cancer. Prostate. 60:32–45.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yanagimoto H, Mine T, Yamamoto K, Satoi S,
Terakawa N, Takahashi K, Nakahara K, Honma S, Tanaka M, Mizoguchi
J, et al: Immunological evaluation of personalized peptide
vaccination with gemcitabine for pancreatic cancer. Cancer Sci.
98:605–611. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yanagimoto H, Shiomi H, Satoi S, Mine T,
Toyokawa H, Yamamoto T, Tani T, Yamada A, Kwon AH, Komatsu N, et
al: A phase II study of personalized peptide vaccination combined
with gemcitabine for non-resectable pancreatic cancer patients.
Oncol Rep. 24:795–801. 2010.PubMed/NCBI
|
|
26
|
Yamada T, Terazaki Y, Sakamoto S,
Yoshiyama K, Matsueda S, Komatsu N, Waki K, Yamada A, Kawahara A,
Kage M, et al: Feasibility study of personalized peptide
vaccination for advanced non-small cell lung cancer patients who
failed two or more treatment regimens. Int J Onco. 46:55–62.
2015.
|
|
27
|
Seki N, Yamaguchi K, Yamada A, Kamizono S,
Sugita S, Taguchi C, Matsuoka M, Matsumoto H, Nishizaka S, Itoh K
and Mochizuki M: Polymorphism of the 5′-flanking region of the
tumor necrosis factor (TNF)-alpha gene and susceptibility to human
T-cell lymphotoropic virus type I (HTLV-1) uveitis. J Infect Dis.
180:880–883. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Seki N, Kamizono S, Yamada A, Higuchi T,
Matsumoto H, Niiya F, Kimura A, Tsuchiya K, Suzuki R, Date Y, et
al: Polymorphisms in the 5′-flanking region of the tumor necrosis
factor-alpha gene in patients with rheumatoid arthritis. Tissue
Antigens. 54:194–197. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang Y and Xian L: The association between
the ERCC1/2 polymorphisms and the clinical outcomes of the
platinum-based chemotherapy in non-small cell lung cancer (NSCLC):
A systematic review and meta-analysis. Tumour Biol. 35:2905–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qiu M, Yang X, Hu J, Ding X, Jiang F, Yin
R and Xu L: Predictive value of XPD polymorphisms on platinum-based
chemotherapy in non-small cell lung cancer: A systematic review and
meta-analysis. PLoS One. 8:e722512013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jain L, Vargo CA, Danesi R, Sissung TM,
Price DK, Venzon D, Venitz J and Figg WD: The role of vascular
endothelial growth factor SNPs as predictive and prognostic markers
for major solid tumors. Mol Cancer Ther. 8:2496–2508. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wassell J: Haptoglobin: Function and
polymorphism. Clin Lab. 46:547–552. 2000.PubMed/NCBI
|
|
33
|
Xie X, Rigor P and Baldi P: MotifMap: A
human genome-wide map of candidate regulatory motif sites.
Bioinformatics. 25:167–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
MotifMap: Genome-wide maps of regulatory
elements. http://motifmap.ics.uci.edu/Accessed July 31,
2015.
|
